Nano Today is a prestigious journal published by ELSEVIER SCI LTD that stands at the forefront of nanoscience and nanotechnology research. With an impact factor that underscores its significance, this journal has achieved remarkable rankings in several key categories as of 2023, including Q1 positions in Bioengineering, Biomedical Engineering, Biotechnology, Materials Science, and Pharmaceutical Science, making it an essential resource for scholars and professionals alike. ISSN 1748-0132 and E-ISSN 1878-044X, the journal serves as a vital platform for disseminating cutting-edge research findings and innovative applications in the field. Although open access options are not available, the journal's rich repository of peer-reviewed articles provides invaluable insights into the latest advancements in nanotechnologies. Based in the Netherlands, Nano Today not only connects a global network of researchers but also propels forward the conversation on the transformative potential of nanomaterials across multiple disciplines. With a commitment to advancing knowledge and fostering innovation, Nano Today is an indispensable tool for academics and practitioners dedicated to pushing the boundaries of scientific exploration.

Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.

Advanced NanoBiomed Research is a pioneering open-access journal committed to advancing the interdisciplinary field of nanobiotechnology, published by WILEY-V C H VERLAG GMBH. Since its inception in 2021, this journal has provided a platform for innovative research that bridges the gap between engineering, medicine, and materials science. With impressive rankings in Scopus, positioning it within the top quartiles of various categories, Advanced NanoBiomed Research aims to disseminate high-quality research that contributes to the understanding and application of nanomaterials in biomedical contexts. As it encompasses a wide scope—from applied microbiology to biomaterials—it serves as an essential resource for researchers, professionals, and students eager to explore the cutting-edge developments in the field. The journal promotes a collaborative environment where emerging ideas can flourish, ensuring that vital advancements in nanobiomedicine can be shared and built upon within the scientific community.

International Journal of Pharmaceutics-X is a premier open access journal published by Elsevier, dedicated to advancing knowledge and research in the field of pharmaceutical sciences. Launched in 2019, this journal has quickly ascended to the Q1 category in the 2023 Category Quartiles, reflecting its high impact and the quality of research it promotes. With a current Scopus ranking of #49 out of 183 in the Pharmacology, Toxicology and Pharmaceutics category, this journal occupies the 73rd percentile, showcasing its significant influence within the scholarly community. Emphasizing innovative research and novel applications, the International Journal of Pharmaceutics-X offers a platform for researchers, professionals, and students to disseminate their findings, making crucial contributions to the global pharmaceutical landscape. The journal is based in the Netherlands, presenting a vibrant hub for scientific discourse and collaboration in a rapidly evolving field.

JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE is a leading peer-reviewed journal published by Springer, dedicated to advancing the field of biomedical materials science. With an ISSN of 0957-4530 and E-ISSN 1573-4838, this Open Access journal has been committed to providing researchers and professionals with freely accessible, high-quality research since 2021. It features an extensive scope spanning bioengineering, biomaterials, biomedical engineering, and biophysics, reflecting its significant impact within these interdisciplinary domains. Recognized within the Q2 category of the 2023 rankings in multiple fields, the journal proudly positions itself as a crucial resource for innovative materials that contribute to advancements in medical applications. With impressive Scopus rankings, including 26th in Biophysics and 40th in Materials Science for Biomaterials, researchers, students, and industry professionals alike can rely on this publication for cutting-edge insights that drive the future of medical materials and technologies. Based in Dordrecht, Netherlands, the journal provides a vibrant platform for sharing groundbreaking discoveries and fostering collaborative research among a global audience.

Nanomedicine-Nanotechnology Biology and Medicine is a leading journal published by Elsevier, dedicated to the exploration of innovative applications of nanotechnology in the fields of biology and medicine. With an ISSN of 1549-9634 and an E-ISSN of 1549-9642, this esteemed journal provides a platform for high-quality research, comprehensively covering areas including bioengineering, biomedical engineering, pharmaceutical science, and nanoscience. Notably, it holds a significant position in various categories with a Q2 ranking in multiple disciplines and a prestigious Q1 ranking in Pharmaceutical Science, emphasizing its impact within the scientific community. By facilitating access to cutting-edge studies and advancements, Nanomedicine-Nanotechnology Biology and Medicine serves as an essential resource for researchers, professionals, and students alike, contributing significantly to the ongoing development of nanomedicine and its pivotal role in improving healthcare outcomes. The journal operates without open access; however, it remains committed to disseminating valuable knowledge to a global audience.

JOURNAL OF DRUG TARGETING, published by Taylor & Francis Ltd, is a premier academic journal dedicated to advancing the field of pharmaceutical sciences with a strong focus on drug delivery and targeting methodologies. With an impressive impact factor and recognized as a Q1 journal in the Pharmaceutical Science category, it ranks #23 out of 183 in Pharmacology, Toxicology and Pharmaceutics, placing it within the top 13% of journals in its field. The journal provides a platform for interdisciplinary research, showcasing innovative techniques and breakthrough findings that serve to improve therapeutic efficacy through precision targeting. Although it operates under a subscription model, researchers benefit from extensive access to pivotal studies spanning from 1986 to 2024. The JOURNAL OF DRUG TARGETING aims to foster collaboration among academics, professionals, and students, making it an essential resource for those seeking to leverage the latest advancements in drug development and delivery systems for improved healthcare outcomes.

Theranostics is a premier journal in the field of Medicine and Pharmacology, published by IVYSPRING INT PUBL. With its commitment to open access since 2011, it facilitates the widespread dissemination of innovative research, fostering collaboration and advancements in therapeutic diagnostics. The journal proudly holds a Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, Toxicology and Pharmaceutics, as of 2023, showcasing its esteemed position within the scientific community. Recognized globally, it ranks in the top 1%, with Scopus rankings placing it as 4th out of 398 in Medicine and 1st out of 43 in Pharmacology. Theranostics serves as a crucial platform for researchers, professionals, and students to explore cutting-edge developments as it converges multidisciplinary approaches to enhance patient care and treatment efficacy. With a focus on bridging experimental research and clinical applications, the journal is instrumental in shaping future therapies and diagnostic strategies.

European Journal of Medicinal Chemistry, a premier publication by Elsevier France-Editions Scientifiques Médicales Elsevier, has been at the forefront of advancing medicinal chemistry since its inception in 1974. With an impressive impact factor and ranking in the Q1 quartile across multiple categories including Drug Discovery, Medicine (miscellaneous), Organic Chemistry, and Pharmacology, this journal delivers cutting-edge research and reviews that are vital for researchers and professionals in the field. The journal’s scope encompasses the design, synthesis, and evaluation of biological activity of bioactive compounds, making it a critical resource for those looking to innovate in drug development and therapeutic strategies. Although currently not open access, subscribers can benefit from its diverse range of high-quality articles, ensuring the dissemination of knowledge in the ever-evolving landscape of medicinal chemistry. The European Journal of Medicinal Chemistry continues to play a pivotal role in shaping the future of pharmacological research and its application, thus appealing to an audience dedicated to making impactful scientific contributions.

Current Cancer Therapy Reviews, an esteemed journal published by Bentham Science Publishers Ltd, serves as a critical resource in the fields of cancer research, molecular medicine, and oncology. With an ISSN of 1573-3947 and an E-ISSN of 1875-6301, this journal provides a platform for the rapid dissemination of reviews that articulate the latest advancements and therapeutic strategies in cancer treatment. Although it currently holds a Q4 classification in its respective categories, the journal's commitment to quality scholarship is evident in its engagement with an expansive range of topics impacting cancer care. Operating from the United Arab Emirates since its inception in 2006, it is an essential tool for researchers, clinicians, and students aiming to stay abreast of the evolving landscape of cancer therapy. The journal emphasizes open access to knowledge, fostering a collaborative environment for innovative research. For those looking to deepen their understanding of contemporary cancer therapies, Current Cancer Therapy Reviews is a valuable addition to their academic resources.